Clinical Trials Directory

Trials / Completed

CompletedNCT04539834

Electrolyte State in Patients With COVID-19

Status
Completed
Phase
Study type
Observational
Enrollment
983 (actual)
Sponsor
Zagazig University · Other Government
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Initial case reports and cohort studies have described many clinical characteristics of patients with coronavirus disease 2019 (COVID-19), an emerging infectious disorder caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In early COVID-19 studies, some evidence has been provided that electrolyte disorders may also be present upon patients' presentation, including sodium, potassium, chloride and calcium abnormalities the aim of the study is Identification of elements that affect COVID-19 pathology to improve survival and decrease mortality rate.

Detailed description

SARS-CoV-2 invades human cells through binding angiotensin I converting enzyme 2 (ACE2) on the cell membrane. ACE2 is widely distributed in many types of human tissues, especially in the vital organs, such as heart, liver, kidney, and lungs. ACE2 is viewed as the principal counter-regulatory mechanism for the main axis of renin-angiotensin system (RAS) that is an essential player in the control of blood pressure and electrolyte balance. The final effect is to increase reabsorption of sodium and water, and thereafter increase blood pressure and excretion of potassium (K+). Besides, patients with COVID-19 often had gastrointestinal symptoms such as diarrhea and vomiting Early studies proved that high percentage of COVID-19 patient were presented with electrolyte disorders, including sodium, potassium, chloride and calcium abnormalities. Such electrolyte disturbances have important implications not only for patient management but also for identifying potential pathophysiologic mechanisms underlying COVID-19 that could drive novel therapeutic opportunities

Conditions

Interventions

TypeNameDescription
OTHERelectrolytesmeasuring level of electrolytes

Timeline

Start date
2020-05-01
Primary completion
2021-08-01
Completion
2021-10-30
First posted
2020-09-07
Last updated
2021-11-23

Locations

1 site across 1 country: Egypt

Source: ClinicalTrials.gov record NCT04539834. Inclusion in this directory is not an endorsement.